State Street Corp Buys 9,400 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

State Street Corp boosted its stake in Delcath Systems, Inc. (NASDAQ:DCTH) by 12.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 85,457 shares of the company’s stock after acquiring an additional 9,400 shares during the period. State Street Corp owned 0.27% of Delcath Systems worth $772,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DCTH. Polar Asset Management Partners Inc. purchased a new position in Delcath Systems in the third quarter valued at approximately $1,594,000. Shellback Capital LP purchased a new stake in Delcath Systems in the second quarter worth $1,353,000. Principal Financial Group Inc. bought a new stake in shares of Delcath Systems in the third quarter valued at $808,000. Renaissance Technologies LLC purchased a new position in shares of Delcath Systems during the 2nd quarter valued at $694,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Delcath Systems during the 2nd quarter worth $370,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Stock Up 4.7 %

Shares of DCTH opened at $12.61 on Friday. Delcath Systems, Inc. has a twelve month low of $3.70 and a twelve month high of $13.30. The stock has a market cap of $403.19 million, a PE ratio of -9.34 and a beta of 0.85. The business’s 50-day moving average price is $11.01 and its 200-day moving average price is $9.54.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DCTH. Canaccord Genuity Group restated a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research note on Monday, November 11th. Finally, Stephens reiterated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Delcath Systems presently has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.